Skip to content

Bioalmanac

Tesamorelin / Ipamorelin

Tesa ipa · Tesa/Ipa blend · tesamorelin with ipamorelin

Preclinical

Status reviewed 25 Aug 2026

Prohibited in sport

An approved GHRH analogue paired with a ghrelin agonist. Sold at three different splits, which matters more here than in most blends.

Storage

Freeze-dried powder
Refrigerated at 2–8 °C, protected from light.
After mixing
Refrigerated at 2–8 °C and used within about 30 days. A blend cannot be split. A contaminated vial takes every component with it.
Long-term, frozen
Unopened powder is stable at −20 °C or colder.

Reconstitution — 10 mg vial, 300 mcg dose

On a 1 mL U-100 syringe. Check every figure against your own vial before drawing.

Water addedConcentrationVolume to drawUnitsDoses per vial
1 mL10 mg/mL0.03 mL3 units33.3
2 mL5 mg/mL0.06 mL6 units33.3
3 mL3.333 mg/mL0.09 mL9 units33.3
5 mL2 mg/mL0.15 mL15 units33.3

Dose ranges reported in sources

Descriptions of what sources report, not recommendations.

GoalRangeFrequencySource
Commonly described community protocol300–500 mcgOnce daily before bed, 5 days a weekCommunity practice

When to stop

  • Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.
  • Persistent numbness or tingling in the hands.
  • New or worsening joint swelling.

Tesamorelin is approved by the FDA for HIV-associated lipodystrophy. Ipamorelin is approved nowhere, and the mixture is approved nowhere. Sold as a research chemical at several ratios.

Arithmetic on values you enter. Not medical advice. Not reviewed by a clinician. · bioalmanac.com/peptides/tesamorelin-ipamorelin-blend

Use your browser’s print dialog and choose “Save as PDF”. This block is hidden when printed.